arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

EXAGEN INC.

XGN
$8.55 ▼ -0.21 (-2.45%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
9 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

EXAGEN INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $184.3M
Dividend Yield —
Revenue Growth 19.7% ↗
Op. Margin -21.1% ↗
ROIC -27.5% ↗
FCF / Share $-0.66 ↗
Trailing P/E —
Price / Book 11.2x
FCF Yield —
Debt / Equity 1.31
info Valuation on last close. End-of-day price, Sep 23, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$66.58M
↑ +19.7% —
Net Income Profit after all expenses
$-19.95M
↓ -32.0% —
Operating Margin Operating profit as % of sales
-21.1%
↑ +13.8% 10th
FCF / Share Free cash flow per share
$-0.66
↑ +12.7% —
Long-Term Debt Long-term obligations
$22.91M
↑ +13.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns ↓
7
Financial Health ↑
29
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters